Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Trial of Efgartigimod PH20 SC in Primary Immune Thrombocytopenia
NCT04812925Phase 3Active, not recruiting
- Sponsor
- argenx
- Start
- Nov 2021
- Primary completion
- Oct 2027
- Modality
- Antibody Fragments
- Countries
- 25
01
Overview
A Phase 3 trial of efgartigimod alfa in primary immune thrombocytopenia (ITP), sponsored by argenx. Started Nov 2021; status: active, not recruiting.
02
Drugs
efgartigimod alfa
03
Conditions
primary immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT04812925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04812925.